Physician profile
Garrison B Smith
NPI 1356561450
$18,954.66
in general payments reported to CMS, 2019-2025
29 companies · $2,079 in 2025
The $2,079 reported for 2025 was more than what 82% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,982 · 2020: $73.08 · 2021: $3,248 · 2022: $7,681 · 2023: $974 · 2024: $918 · 2025: $2,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834 · Travel and Lodging: $1,325 · Education: $795 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.47 |
| Travel and Lodging | $1,325.37 |
| Education | $794.69 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $15,337.94 | 2019-2025 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $1,544.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $374.73 | 2020-2025 | Gattex |
| Allergan, INC. | $299.06 | 2020-2022 | |
| Ethicon US, LLC | $216.43 | 2019 | |
| Abbvie INC. | $198.53 | 2023-2025 | Strattice Reconstructive Tissue Matrix Bps |
| Portola Pharmaceuticals, LLC | $171.66 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $134.91 | 2019-2025 | Exparel |
| Lemaitre Vascular, INC. | $88.66 | 2019-2023 | Flexcel Carotid Shunt |
| W. L. Gore & Associates, INC. | $74.89 | 2025 | Gore Bio-A Tissue Reinforcement, Gore Synecor Biomaterial, Gore Synecor Preperitoneal Biomaterial |
| Tela Bio, INC. | $56.08 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Boston Scientific Corporation | $47.57 | 2019-2023 | Spyglass |
| Conmed Corporation | $39.87 | 2019 | |
| Innocoll Pharmaceuticals Limited | $39.32 | 2021-2022 | |
| Shire North American Group INC | $38.46 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $30.05 | 2024 | Excelsius Deformity |
| Cvrx, INC. | $27.25 | 2024 | Barostim Neo System |
| Silk Road Medical, INC. | $26.56 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Kerecis Limited | $24.83 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Merck Sharp & Dohme LLC | $21.49 | 2023 | |
| Smith+Nephew, INC. | $21.08 | 2019 | |
| Ambu INC. | $20.42 | 2022 | |
| Enterra Medical, INC. | $19.68 | 2024 | |
| Cook Medical LLC | $19.50 | 2023 | Zilver Ptx |
| Tactile Systems Technology INC | $19.45 | 2021 | |
| Endogastric Solutions, INC | $18.80 | 2022 | |
| Z-Medica, LLC | $16.53 | 2020 | |
| Medtronic, INC. | $14.65 | 2024 | Truclear |
| Covidien Lp | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrison Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.